Eli Lilly said on Thursday a late-stage trial showed its weight-loss drug Zepbound, used with its psoriatic arthritis ...

In an open-label phase 3b trial, the co-administration of Lilly’s IL-17A antagonist Taltz (ixekizumab) and dual GIP/GLP-1 ...

Patients given a combination of Eli Lilly & Co.’s weight-loss shot Zepbound and arthritis drug Taltz saw a greater ...

Eli Lilly said Thursday that adding its weight loss drug Zepbound on top of its immunology therapy Taltz helped obese ...

Eli Lilly will buy autoimmune drug developer Ventyx Biosciences for $1.2 billion in cash, the companies said on Wednesday, ...

The first pills are expected to hit the market next month and attract people who don’t want to give themselves shots.

Eli Lilly will buy autoimmune drug developer Ventyx Biosciences for $1.2 billion in cash, the companies said on Wednesday, ...

Eli Lilly and Company rated Buy: incretin/obesity growth, ZEPBOUND & orforglipron access strategy, pipeline deals, ...

Eli Lilly has dominated headlines in recent months, recently taking the crown as the most valuable company in the biopharma ...

The fierce rivalry between Novo Nordisk and Eli Lilly is alive and well, as the two companies are expected to face off with ...